Proteolytic Processing of CD44 and Its Implications in Cancer

Table 1

Tumors and their cancer stem cell mark.

Tumor	Cancer stem cell phenotype
Brain	CD44^+/CD133^+/NPM1^+/CD90^+/CD49f^+
Breast	CD44^+/CD24^-/low/CD29^+/ALDH1A3^+h/CD164^+
Colon	CD44^+/CD133^+/CD26^+/ALDH1^+/EpCAM^+h
Head and neck	CD44^+/CD271^+
Leukemia	CD44^+/CD123^+/CD34^+/CD38^-
Liver	CD44^+/CD133^+/CD24^+/EpCAM^+
Lung	CD44^+/CD133^+/ALDH1^+/CDw338^h
Ovarian	CD44^+/CD24^+/CD117^+/CD133^+/ALDH1^+
Melanoma	CD44^+/CD15^+/CD117^+/CD34^+/CD20^+/ALDH1^h
Pancreas	CD44^+/CD133^+/CD24^+/EpCam^+
Prostate	CD44^+/CD133^+/21^hintegrin

There are innumerable CSC phenotype combinations that depend on the histological type and the recurrence rate. Also, designated as breast cancer resistance protein or ATP-binding cassette transporter G2. Is the noncovalent heterodimer CD49b/CD29.